149 related articles for article (PubMed ID: 38536949)
41. Engineered Exosomes Carrying miR-588 for Treatment of Triple Negative Breast Cancer Through Remodeling the Immunosuppressive Microenvironment.
Zhang Z; Luo X; Xue X; Pang M; Wang X; Yu L; Qian J; Li X; Tian M; Lu A; Lu C; Liu Y
Int J Nanomedicine; 2024; 19():743-758. PubMed ID: 38283199
[TBL] [Abstract][Full Text] [Related]
42. (cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131.
Liu S; Liu H; Sun H; Deng S; Yue L; Weng Z; Yang J; Zuo B; He Y; Zhang B
Anticancer Drugs; 2022 Jan; 33(1):19-29. PubMed ID: 34261920
[TBL] [Abstract][Full Text] [Related]
43. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
44. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
[TBL] [Abstract][Full Text] [Related]
45. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers.
Shen L; Li J; Liu Q; Song W; Zhang X; Tiruthani K; Hu H; Das M; Goodwin TJ; Liu R; Huang L
ACS Nano; 2018 Oct; 12(10):9830-9841. PubMed ID: 30253648
[TBL] [Abstract][Full Text] [Related]
46. Fenton-reaction-stimulative nanoparticles decorated with a reactive-oxygen-species (ROS)-responsive molecular switch for ROS amplification and triple negative breast cancer therapy.
Zhang J; Zuo T; Liang X; Xu Y; Yang Y; Fang T; Li J; Chen D; Shen Q
J Mater Chem B; 2019 Dec; 7(45):7141-7151. PubMed ID: 31663577
[TBL] [Abstract][Full Text] [Related]
47. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
48. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
49. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
50. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
[TBL] [Abstract][Full Text] [Related]
51. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
52. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
53. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
54. Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
Zhang B; Jin K; Jiang T; Wang L; Shen S; Luo Z; Tuo Y; Liu X; Hu Y; Pang Z
Sci Rep; 2017 Aug; 7(1):10071. PubMed ID: 28855534
[TBL] [Abstract][Full Text] [Related]
55. Prodrug nanoparticles potentiate tumor chemo-immunometabolic therapy by disturbing oxidative stress.
Zhao H; Li Y; Shi H; Niu M; Li D; Zhang Z; Feng Q; Zhang Y; Wang L
J Control Release; 2022 Dec; 352():909-919. PubMed ID: 36370878
[TBL] [Abstract][Full Text] [Related]
56. Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment.
He Z; Zhang H; Li H; Wang Y; Qian J; Cai X; Sun L; Huang J
Oxid Med Cell Longev; 2020; 2020():7152173. PubMed ID: 33488930
[TBL] [Abstract][Full Text] [Related]
57. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
58. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
59. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
60. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]